Evrofarma SA (EVROF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evrofarma SA (EVROF) has a cash flow conversion efficiency ratio of 0.108x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.52 Million ≈ $1.77 Million USD) by net assets (€14.03 Million ≈ $16.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Evrofarma SA (EVROF) net asset quality to measure how much of total assets are equity-financed.
Evrofarma SA - Cash Flow Conversion Efficiency Trend (2014–2022)
This chart illustrates how Evrofarma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Evrofarma SA earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Evrofarma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evrofarma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Nippon Rubber Industry Public Co. Ltd
BK:TNR
|
0.025x |
|
HeiTech Padu Bhd
KLSE:5028
|
-0.771x |
|
Techbond Group Bhd
KLSE:5289
|
0.052x |
|
EgnsINVEST Ejendomme Tyskland A/S
CO:EGNETY
|
0.003x |
|
ABCO Electronics Co. Ltd
KQ:036010
|
-0.004x |
|
Experience Co Ltd
AU:EXP
|
0.044x |
|
York Timber Holdings Ltd
JSE:YRK
|
0.024x |
|
Astra Exploration Inc
V:ASTR
|
-0.746x |
Annual Cash Flow Conversion Efficiency for Evrofarma SA (2014–2022)
The table below shows the annual cash flow conversion efficiency of Evrofarma SA from 2014 to 2022. For the full company profile with market capitalisation and key ratios, see Evrofarma SA (EVROF) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €14.03 Million ≈ $16.40 Million |
€2.44 Million ≈ $2.85 Million |
0.174x | +372.38% |
| 2021-12-31 | €12.61 Million ≈ $14.74 Million |
€-805.00K ≈ $-941.13K |
-0.064x | -156.73% |
| 2020-12-31 | €12.95 Million ≈ $15.14 Million |
€1.46 Million ≈ $1.70 Million |
0.113x | -24.84% |
| 2019-12-31 | €11.87 Million ≈ $13.88 Million |
€1.78 Million ≈ $2.08 Million |
0.150x | -23.84% |
| 2018-12-31 | €11.65 Million ≈ $13.63 Million |
€2.29 Million ≈ $2.68 Million |
0.197x | -32.08% |
| 2017-12-31 | €10.73 Million ≈ $12.54 Million |
€3.11 Million ≈ $3.63 Million |
0.290x | +173.21% |
| 2016-12-31 | €10.20 Million ≈ $11.93 Million |
€1.08 Million ≈ $1.26 Million |
0.106x | -25.34% |
| 2015-12-31 | €9.79 Million ≈ $11.45 Million |
€1.39 Million ≈ $1.63 Million |
0.142x | +51.87% |
| 2014-12-31 | €9.27 Million ≈ $10.83 Million |
€866.00K ≈ $1.01 Million |
0.093x | -- |
About Evrofarma SA
Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products. Evrofarma SA was founded in 1991 and is headquartered in Didymoteicho, Greece.